A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer
Sponsor study identifier
Secondary identifiers
interventional
18
1 country
1
Study Start
January 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2007
Actual (reported)Study Completion
October 2007
Actual (reported)Patients who have limited stage small cell lung cancer are presently treated with chemotherapy and radiation therapy (RT). Despite this aggressive treatment the vast majority of patients will have their cancer recur after treatment. A recurrence is not curable at this time, therefore efforts to reduce recurrence rates are desirable. Due to the sensitivity of surrounding structures in the chest to radiation, it has not been possible to give doses that can cure most tumours. Three-dimensional conformal radiotherapy is a special form of radiation therapy that allows doctors to reduce the amount of radiation dose to normal tissues and therefore reduce toxicity and in turn, let them safely increase the dose to tumours. The purpose of this study is to determine whether the combination of three-dimensional conformal radiotherapy and chemotherapy will be a more effective treatment. If the treatment is found to be safe for the first group of patients, then the total radiation dose will be increased for the next group of patients who are treated on this study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2003
Date type not reportedThis date has not been verified as actual or estimated.
August 3, 2005
Actual (reported)August 5, 2005
Actual (reported)September 2007
Actual (reported)October 2007
Actual (reported)grade 3 RT toxicity rate
disease free
overall survival
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
Peter Venner, MD
AHS Cancer Control Alberta
First Submitted
August 3, 2005
First Posted
August 5, 2005
Study Start
January 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2007
Actual (reported)A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
Contact the study team to confirm eligibility.
Study Completion
October 2007
Actual (reported)Last Updated
February 24, 2016
Record last verified: 2011-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: